ES2529211T3 - Optimización e individualización de la selección y dosificación de medicamentos - Google Patents

Optimización e individualización de la selección y dosificación de medicamentos Download PDF

Info

Publication number
ES2529211T3
ES2529211T3 ES11185491.5T ES11185491T ES2529211T3 ES 2529211 T3 ES2529211 T3 ES 2529211T3 ES 11185491 T ES11185491 T ES 11185491T ES 2529211 T3 ES2529211 T3 ES 2529211T3
Authority
ES
Spain
Prior art keywords
functional
drug
allele
genes
metabolizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11185491.5T
Other languages
English (en)
Inventor
Tracy A. Glauser
Richard Wenstrup
Alexander A. Vinks
John Pestian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Application granted granted Critical
Publication of ES2529211T3 publication Critical patent/ES2529211T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Primary Health Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)

Abstract

Un método para la determinación de una dosis de partida de un fármaco neuropsiquiátrico para su administración a un paciente en necesidad del mismo, método que comprende (a) recibir en un procesador la dosis de fármaco habitual para la población que representa al paciente (Dpop); (b) recibir en un procesador el genotipo de un paciente para un conjunto de genes que comprende los siguientes genes del citocromo P450 (CYP): CYP2D6, CYP2C19 y CYP2C9; (c) determinar el número de alelos funcionales y no funcionales de cada gen basándose en dicho genotipo; (d) clasificar el paciente en un subgrupo del fenotipo metabolizador basándose en el número de alelos funcionales de cada uno de los genes del CYP, en el que el subgrupo metabolizador genes se elige de entre uno de los siguientes: metabolizador rápido (EM) >= 2 alelos funcionales, metabolizador intermedio (IM) >= 1 alelo funcional, y metabolizador lento (PM) >= 0 alelos funcionales; (e) recibir en un procesador la frecuencia de los subgrupos de fenotipos metabolizadores en la población; y (f) determinar, a través de un procesador, la dosis de partida del fármaco expresada como un porcentaje basado en el número de alelos no funcionales como sigue: Porcentaje de reducción para un alelo no funcional: Porcentaje de reducción para dos alelos no funcionales: en la que el DRX % es la recomendación de dosis para el subgrupo metabolizador X expresada como un porcentaje de la dosis habitual del fármaco (Dpop), en la que Dpop >= fPM(DPM) + fIM(DIM) + fEM(DEM), y en la que DEM se reduce en un 20 % por cada alelo no funcional CYP2D6 o CYP2C19, y en un 40 % por cada alelo no funcional CYP2C9.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
E11185491
29-01-2015
específicos de un medicamento, d) enzimas, transportadores o receptores que afectan a otros fármacos que interactúan con el medicamento en cuestión o e) funciones corporales que afectan a las actividades del medicamento en cuestión. En una forma de realización de la invención, algunos loci de interés incluyen, pero no se limitan a, cinco genes del citocromo P450, el gen transportador de la serotonina, el gen transportador de la 5 dopamina y los genes receptores de la dopamina. Los cinco genes del citocromo P450 pueden codificar para la CYP2D6, para la CYP1A2, para la CYP2C19, para la CYP2C9 y para la CYP2E1. Algunos alelos de particular interés incluyen, pero no se limitan a, el alelo CYP1A2*1A o el 1A2*3, el alelo CYP2C19*1A, el 2C19*1B o el 2C19*2A y el alelo CYP2D6*1A, el 2D6*2, el 2D6*2N, el 2D6*3, el 2D6*4, el 2D6*5, el 2D6*6, el 2D6*7, el 2D6*8, el 2D6*10, el 2D6*12 o el 2D6*17. Los genes de los receptores de la serotonina codifican para los receptores de la
10 serotonina 1A, 1B, 1D, 2A o 2C y los genes de los receptores de la dopamina codifican para los receptores de la dopamina D1, D2, D3, D4, D5 y D6. El gen transportador de la serotonina también es una parte importante del genotipo. Algunos genes, alelos, polimorfismos y loci adicionales de interés se presentan en Tablas 1 y 2.
Tabla 1 Genes del citocromo P450
Gen del citocromo P450
Alelo Polimorfismo
1A1
* 1A Ninguno
* 2
A2455G
* 3
T3205C
*4
* 4 C2453A
1A2
* 1A * IF * 3 Ninguno -164C > A G1042A
1B1
* 1 Ninguno
* 2
R48G
* 3
L432V
* 4
N453S
* 11
V57C
* 14
E281X
* 18
G365W
* 19
P379L
* 20
E387K
* 25
R469W
2A6
* 1A Ninguno
* 1B
CYP2A 7 translocado al extremo 3'
* 2
T479A
* 5
* 1B + G6440T
2B6
* 1 * 1'2
R22C
* 1'3
S259C
* 4
K262R
* 5
R487C
* 6
Q172H; K262R
* 7
Q172H; I < 262R; R487C
2C8
* 1A Ninguno
* 1B
-271C > A
* 1C
-370T > G
* 2
I269F
* 3
R139K; K399R
* 4
I264M
8
E11185491
29-01-2015
Gen del citocromo P450
Alelo Polimorfismo
2C9
* 1 Ninguno
* 2
R144C
* 3
I359L
* 5
D360E
2C18
rot m2 T204A A460T
2C19
* 1A Ninguno
* IB
I331V
* 2A
Defecto de ayuste
* 2B
Defecto de ayuste; E92D
* 3
Nuevo codón de detención 636G > A
* 4
Codón de inicio GTG, 1A > G
*5(A,B)
* 5 (A, B) 1297C > T, cambio de aminoácido (R433W)
* 6 * 7
395G > A, cambio de aminoácido (R132Q) IVS5+2T > A, defecto de ayuste
* 8
358T > C, cambio de aminoácido (WI20R)
2D6
* IA * 2 * 2N * 3 * 4 * 5 * 6 * 7 * 8 * 10 * 12 * 17 * 35 Ninguno G1661C, C2850T Duplicación del gen Deleción A2549 G1846A Deleción del gen Deleción T1707 A2935C G1758T CIOOT G124A CIO23T, C2850T G31A
2E1
* IA * IC, * 1D * 2 * 4 * 5 * 5 * 7 * 7 * 7 Ninguno (repeticiones de 6 o e 8 pb) G1132A G476A G(-1293)C C(-IO53)T T(-333)A G(-71)T A(-353)G
9
E11185491
29-01-2015
n del citocromo P450
Alelo Polimorfismo
34A
* IA * IB * 2 * 5 * 6 * 12 * 13 * 15A * 17 * 18A Ninguno A(-392)G Cambio de aminoácido (S222P) Cambio de aminoácido (P218R) Cambio del marco de lectura, 831 ins A Cambio de aminoácido (L373F) Cambio de aminoácido (P416L) Cambio de aminoácido (RI62Q) Cambio de aminoácido (F189S, disminuido) Cambio de aminoácido (L293P, aumentado)
35A
* 1A Ninguno
* 3
A6986G
* 5
T12952C
* 6
G14960A
Tabla 2: Genes que no son del citocromo P450
Gen
Símbolo Polimorfismo
Transportador de dopamina
DATI, SLC6A3 VNTR de 40 pb 10 repeticiones del alelo G710A, Q237R C124T, L42F
Receptor de dopamina D1
DRDI DRD 1 B2 T244G C179T G127A Tl1G C81T T5950, S199A G150T, R50S C1100, T37R AI09C, T37P
Receptor de dopamina D2
DRD2 TaqI A AI051G, T35A C932G, S311 C C928, P31 OS G460A, V1541
Receptor de dopamina D3
DRD3 Ball en el exón I MspI DRD31 Gly/Ser (alelo 2) A250, S9G
Receptor de dopamina D4
DRD4 48 repeticiones en exón 3 7 repeticiones del alelo Inserción / deleción de 12/13 pb T581G, V194G C841G, P281A
Receptor de dopamina D5
DRD5 T978C L88F A889C,T297P G1252A, V4181 G181A, V61M G185C, C62S T2630, R88L G1354A, W455
10
E11185491
29-01-2015
Gen
Símbolo Polimorfismo
Hidroxilasa de triptófano
TPH A218C A779C G-5806T
Gen
Símbolo Polimorfismo
A-6526G (CT)m(CAMCT)p alelo 194 en la UTR en 3’, distante 5657 pb del exón 11
Transportador de serotonina
5-HTTR Repetición del promotor (inserción de 44 pb (L)/deleción(S) (L = forma larga; S = forma ShOli) Exón 2 variable Repetición A1815C G603C G167C
Receptor de serotonina 1A
HTR1A RsaI G815A, G272D G656T, R219L C548T, P551 l A82G,128V G64A, G22S C47T, P16L
Receptor de serotonina 1B
HTR1B G861C
T371G, T655C, F219L
G861C, V287V T371G, F124C T655C, F219L A1 099G, I367V G1120A, E374K
Receptor de serotonina 1D
HTR1D G506T C173T C794T, S265L
Receptor de serotonina 2A
HTR2A T102C T516C C74A T102C T516C C1340T C1354T
Receptor de serotonina 2C
HTR2C G796C ClOG, L4V G68C, C23S
Catecol-o-metiltransferasa
COMT G158A (también conocido como Val/Met) G214T A72S G101C C34S G473A
En una forma de realización de la invención, se utilizan los métodos informatizados y/o los métodos asistidos por ordenador (incluyendo algoritmos informáticos) para seleccionar un régimen de dosificación para un paciente en 5 necesidad de un medicamento neuropsiquiátrico. Un gen importante en el grupo neuropsiquiátrico es CYP2D6. Los sustratos de la CYP2D6 normalmente son bases débiles con el sitio de unión catiónico localizado lejos del átomo de carbono que se va a oxidar. En particular, algunos sustratos de la CYP2D6 incluyen amitriptilina, nortriptilina, haloperidol y desipramina. Algunos individuos tienen alteradas las secuencias génicas de la CYP2D6 lo que da como resultado la síntesis de enzimas desprovistas de actividad catalítica, o de enzimas con una actividad catalítica 10 disminuida. Estos individuos metabolizan lentamente los SSRIs y los antidepresivos tricíclicos (TCAs). También se ha observado la duplicación / multiplicación del gen funcional CYP2D6 y da como resultado un metabolismo ultrarrápido de los SSR1s y de otros fármacos. Los individuos que no tienen polimorfismos, deleciones o duplicaciones inactivadoras tienen el fenotipo de un metabolizador farmacológico rápido y se denominan CYF2D6*1. Los alelos CYP2D6*3 y *4 suponen prácticamente el 70 % de todas las deficiencias que dan como resultado un 15 fenotipo metabolizador lento. El polimorfismo responsable de CYP2D6*3 (2549A > del) produce un cambio en marco en el ARNm. Un polimorfismo implicado con el alelo CYP2D6*4 (1846G > A) desestabiliza el ayuste del ARNm. Estos cambios producen formas truncadas de la CYP2D6 desprovistas de actividad catalítica. Otros metabolizadores
11
imagen7
imagen8
imagen9
imagen10
imagen11
E11185491
29-01-2015
a.
es apreciable que cada alelo no funcional adicional altera la recomendación de dosis en al menos un 20 %
b.
existe una relación entre "dosis genética" -"reducción de la dosis" que parece ser constante a través de estos 3 genes CYP450. Puede usarse esta metodología para solidificar la importancia de los subsiguientes genes DM y para cuantificar su efecto en unidades MDA.
5 c. 2D6 y 2C 19 tienen 1 unidad MDA por alelo no funcional
d. 2C9 tiene 2 unidades MDA por alelo no funcional. Esto implica que el fármaco metabolizado a través de 2C9 tiene una variabilidad muy amplia en los requisitos de dosis. Esto confirma la impresión clínica sobre estos fármacos (warfarina, fenitoína).
10 Tabla 3
2D6
2D6
PM (%) IM (%) EM (%) UM (%)
Antipsicóticos
A atomoxetina 20 100 100 100
Psicoestimulantes
B imipramina 28 79 131 182
Antidepresivos
A perfenazina 31 80 129 178
Antidepresivos -TCA
B doxepin 36 82 127 173
Antipsicóticos
B maprotilina 36 82 127 173
Antipsicóticos
B trimipramina 37 91 131 178
Antipsicóticos
A tioridazina 40 85 126 140
Antidepresivos
A deslpramina 42 83 125 167
Antidepresivos
A nortriptilina 53 96 119 152
Antidepresivos -TCA
B clomipramina 60 89 117 146
Antipsicóticos
A olanzapina 61 105 122 139
Antidepresivos -SSRIs
A zuclopentixol 63 90 116 142
Antipsicóticos
A paroxetina 66 90 114 138
Antipsicóticos
A venlafaxina 68 86 109 130
Antipsicóticos
B fluvoxamina 69 93 112 131
Antipsicóticos
A aripiorazol 70 92 113 134
Antipsicóticos
B amitriptilina 73 92 111 130
Antidepresivos
A flupentixol 74 86 116 146
Antidepresivos
B mianserina 74 90 114 134
Antipsicóticos
A haloperidol 76 97 107 126
Antidepresivos -TCA
A trazadona 76 93 110 127
Antidepresivos -SSRIs
B fluoxetina 78 94 107 120
Antidepresivos -TCA
A perazina 86 91 110 117
Antipsicóticos
A risperidona 87 96 106 116
Antidepresivos -TCA
A buproprión 90 97 104 111
Antidepresivos -SSRls
A nefazodona 90 97 105 113
Recuento Promedio Desv. típica
Antidepresivos -SSRIs
A pimozida 95 99 102 105
Antidepresivos -TCA
B citalopram 98 100 101 102
2 al
/ 1
2al
1 al al
0,80
0,00
0,79
0,40 1,98
0,76
0,38 2,00
0,72
0,35 2,02
0,72
0,35 2,02
0,72
0,31 2,35
0,68
0,33 2,10
0,66
0,34 1,98
0,55
0,19 2,87
0,49
0,24 2,04
0,50
0,14 3,59
0,46
0,22 2,04
0,42
0,21 2,00
0,38
0,21 1,78
0,38
0,17 2,26
0,38
0,19 2,05
0,34
0,17 2,00
0,36
0,26 1,40
0,35
0,21 1,67
0,29
0,09 3,10
0,31
0,15 2,00
0,27
0,12 2,23
0,22
0,17 1,26
0,18
0,09 1,90
0,13
0,07 2,00
0,14
0,08 1,88
26
26 25
0,45
0,22 2,10
0,20
0,10 0,48
0,07 0,03 0,03 0,01
17
imagen12
imagen13
imagen14
imagen15
5
10
15
20
25
30
35
40
E11185491
29-01-2015
asociada a esa especialidad. Si no hay ninguna organización científica nacional asociada con la especialidad, entonces el sistema de clasificación por defecto es el sistema de evaluación de la American Academy of Neurology. Después de completar el análisis basado en la evidencia, los datos de eficacia y tolerabilidad para cada fármaco potencial (estratificados por subgrupo de edad y de enfermedad) se resumen de acuerdo con la siguiente Tabla 5 mediante el uso de una escala desde 1+ hasta-1.
Tabla 5: sistema de puntuación farmacológica para los datos de eficacia y tolerabilidad
Puntuación de eficacia o de tolerabilidad
Tipo de dato (mostrados sólo para la eficacia)
1,0
Indicación de la FDA para la afección
0,9
Recomendación de nivel A de las Directrices Basadas en la Evidencia
0,9
Evidencias del metaanálisis de eficacia
0,7
Recomendación de nivel B de las Directrices Basadas en la Evidencia
0,7
Evidencias de un RCT de una mejor eficacia que otro fármaco o que placebo
0,3
Recomendación de nivel C de las Directrices Basadas en la Evidencia
0,3
Evidencias de un ensayo clínico no RCT de eficacia
0,3
Opinión experta -el fármaco es eficaz
0,0
Sin datos
-0,3
Opinión experta -evidencias de empeoramiento
-0,3
Evidencias de un ensayo clínico no RCT de empeoramiento
-0,7
Evidencias de un RCT de una eficacia peor que otro fármaco o que placebo
-0,9
Evidencias del metaanálisis de ausencia de eficacia o de empeoramiento
-0,9
Evidencia de las Directrices Basadas en la Evidencia de ausencia de eficacia o de empeoramiento
-1,0
Contraindicación de la FDA para la afección
Características farmacológicas básicas específicas del fármaco
Las características farmacológicas básicas específicas de fármacos son evaluadas en tres categorías: toxicidad preclínica, variables farmacocinéticas clínicas fundamentales y seguridad del fármaco. Un ejemplo de la categoría de toxicidad preclínica es el índice terapéutico del fármaco. Este se define como la proporción entre DL50 / TD50, en la que la TD50 es la dosis de medicamento que da como resultado que el 50 % de los animales del ensayo consigan el resultado terapéutico deseado, mientras que la DL50 es la dosis de medicamento que da como resultado la muerte del 50 % de los animales del ensayo. Las variables farmacocinéticas clínicas fundamentales incluyen, pero no se limitan a,
i) la biodisponibilidad de un fármaco (fracción de la dosis que alcanza la circulación sistémica como fármaco intacto), ii) la fracción del fármaco circulante no unido (definida por el grado con el que un fármaco se une en plasma el plasma o en la sangre = [concentración de fármaco no unido] / [concentración de fármaco total]), iii) el tipo de metabolismo que experimenta el fármaco (si es lineal o no lineal), iv) el tipo de eliminación que experimenta el fármaco (por ejemplo, el porcentaje de fármaco excretado por vía renal o metabolizado por vía hepática) y v) la semivida del fármaco.
La seguridad del fármaco incluye, pero no se limita a, el riesgo de efectos secundarios potencialmente mortales (reacciones idiosincráticas) y el riesgo de teratogenicidad. Para cada fármaco en consideración, cada variable de las tres categorías se clasifica en una escala desde +1 (más favorable) hasta -1 (más desfavorable).
Factores farmacológicos avanzados específicos del paciente
Los factores farmacológicos avanzados específicos del paciente incluyen i) interacciones bidireccionales farmacocinéticas o farmacodinámicas entre fármacos, y ii) interacciones bidireccionales farmacodinámicas entre el fármaco y la enfermedad. Una interacción farmacocinética entre fármacos se considera potencialmente clínicamente significativa si existe una interacción documentada que demuestre que un fármaco induce o inhibe la actividad de una enzima específica asociada con el metabolismo del otro fármaco en > 20 %. Solo se consideran en el análisis los medicamentos que realmente se están tomando simultáneamente en el momento del análisis. Para las interacciones entre el fármaco y la enfermedad, la palabra "enfermedades" se refiere a todas las formas de alteraciones en la salud que varían desde una única disfunción orgánica (por ejemplo, insuficiencia renal) hasta una enfermedad de todo el cuerpo (por ejemplo, lupus eritematoso sistémico). Las potenciales interacciones entre
22
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
ES11185491.5T 2005-11-29 2006-11-28 Optimización e individualización de la selección y dosificación de medicamentos Active ES2529211T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74043005P 2005-11-29 2005-11-29
US740430P 2005-11-29
US78311806P 2006-03-16 2006-03-16
US783118P 2006-03-16

Publications (1)

Publication Number Publication Date
ES2529211T3 true ES2529211T3 (es) 2015-02-18

Family

ID=38092744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11185491.5T Active ES2529211T3 (es) 2005-11-29 2006-11-28 Optimización e individualización de la selección y dosificación de medicamentos

Country Status (9)

Country Link
US (4) US8589175B2 (es)
EP (4) EP1958111A4 (es)
JP (4) JP2009517186A (es)
AU (1) AU2006320633A1 (es)
CA (3) CA2911569C (es)
DK (1) DK2508621T3 (es)
ES (1) ES2529211T3 (es)
HK (1) HK1244906A1 (es)
WO (1) WO2007064675A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024192543A1 (es) 2023-03-22 2024-09-26 Neomente Corp Método para la selección de medicamentos para el tratamiento de patologías de salud mental

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
JP5348840B2 (ja) 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
US8688385B2 (en) * 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
WO2007104093A1 (en) * 2006-03-10 2007-09-20 Neurotech Research Pty Limited Subject modelling
US8099298B2 (en) * 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
US8732188B2 (en) * 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
JP4882927B2 (ja) * 2007-08-31 2012-02-22 セイコーエプソン株式会社 カテゴリ識別方法
JP2009093334A (ja) * 2007-10-05 2009-04-30 Seiko Epson Corp 識別方法及びプログラム
US20090271164A1 (en) * 2008-01-03 2009-10-29 Peng Joanna Z Predicting long-term efficacy of a compound in the treatment of psoriasis
US20090216561A1 (en) * 2008-02-22 2009-08-27 Swedish Health Services Methods for management of anticoagulation therapy
US20090216563A1 (en) * 2008-02-25 2009-08-27 Michael Sandoval Electronic profile development, storage, use and systems for taking action based thereon
US8255396B2 (en) 2008-02-25 2012-08-28 Atigeo Llc Electronic profile development, storage, use, and systems therefor
US9026369B2 (en) * 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US9449150B2 (en) * 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US8682687B2 (en) * 2008-04-24 2014-03-25 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US8930208B2 (en) 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US8876688B2 (en) 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20090270687A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for modifying bioactive agent use
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US8615407B2 (en) * 2008-04-24 2013-12-24 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US20100030089A1 (en) * 2008-04-24 2010-02-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US8606592B2 (en) * 2008-04-24 2013-12-10 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US9239906B2 (en) 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US7974787B2 (en) * 2008-04-24 2011-07-05 The Invention Science Fund I, Llc Combination treatment alteration methods and systems
US9064036B2 (en) 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100125782A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland Electronic document for automatically determining a dosage for a treatment
US20100125421A1 (en) * 2008-11-14 2010-05-20 Howard Jay Snortland System and method for determining a dosage for a treatment
US8122820B2 (en) * 2008-12-19 2012-02-28 Whirlpool Corporation Food processor with dicing tool
US10853900B2 (en) * 2009-02-09 2020-12-01 Fair Isaac Corporation Method and system for predicting adherence to a treatment
NZ597655A (en) 2009-07-08 2013-05-31 Worldwide Innovative Network Method for predicting efficacy of drugs in a patient
US8909593B2 (en) * 2009-07-10 2014-12-09 Medimpact Healthcare Systems, Inc. Modifying a patient adherence score
US8417660B2 (en) * 2009-07-10 2013-04-09 Medimpact Healthcare Systems, Inc. Modifying a patient adherence score
US20110082867A1 (en) * 2009-10-06 2011-04-07 NeX Step, Inc. System, method, and computer program product for analyzing drug interactions
JP5562209B2 (ja) * 2009-11-04 2014-07-30 第一三共株式会社 医薬の観察研究又は疫学研究のための被験者登録方法
WO2011106364A2 (en) * 2010-02-23 2011-09-01 Farmacia Electronica, Inc. Method and system for consumer-specific communication based on cultural normalization techniques
CA2798481A1 (en) 2010-05-06 2011-11-10 Atigeo Llc Systems, methods, and computer readable media for security in profile utilizing systems
CA2807949C (en) * 2010-08-13 2022-10-25 Intellimedicine, Inc. System and methods for the production of personalized drug products
US8676607B2 (en) 2011-01-10 2014-03-18 Medimpact Healthcare Systems, Inc. Obtaining patient survey results
US20120179481A1 (en) * 2011-01-10 2012-07-12 Medimpact Healthcare Systems, Inc. Recommending Prescription Information
US20140349862A1 (en) * 2011-05-30 2014-11-27 Vuong Ngoc Trieu Methods and compositions for therapeutic drug monitoring and dosing by point of care pharmacokinetic profiling
KR101289307B1 (ko) 2011-08-23 2013-07-24 주식회사 아리바이오 개인별 맞춤 영양제 조제 시스템
EP2754076B1 (en) * 2011-09-08 2021-03-10 Fresenius Medical Care Holdings, Inc. System and method of modeling erythropoiesis and its management
US20130268290A1 (en) * 2012-04-02 2013-10-10 David Jackson Systems and methods for disease knowledge modeling
CA2885834A1 (en) 2012-09-27 2014-04-03 The Children's Mercy Hospital System for genome analysis and genetic disease diagnosis
SG10201907682RA (en) 2012-10-05 2019-10-30 Mould Diane System and method for providing patient-specific dosing as a function of mathematical models
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
US9679111B2 (en) 2012-11-05 2017-06-13 Fresenius Medical Care Holdings, Inc. System and method of modeling erythropoiesis including iron homeostasis
EP4414990A3 (en) 2013-01-17 2024-11-06 Personalis, Inc. Methods and systems for genetic analysis
WO2014116276A1 (en) * 2013-01-24 2014-07-31 Kantrack Llc Individualized medicine system
MX2015009780A (es) * 2013-01-29 2016-04-04 Molecular Health Gmbh Sistemas y metodos para soporte de decision clinica.
US20160335412A1 (en) * 2013-01-30 2016-11-17 Geoffrey Tucker Systems and methods for predicting and adjusting the dosage of medicines in individual patients
US10210312B2 (en) * 2013-02-03 2019-02-19 Youscript Inc. Systems and methods for quantification and presentation of medical risk arising from unknown factors
US10262112B2 (en) 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
WO2014121257A1 (en) * 2013-02-04 2014-08-07 Sano Informed Prescribing, Llc Prescription decision support system and method using comprehensive multiplex drug monitoring
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20140274763A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to pain treatments
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US10853451B2 (en) * 2013-06-06 2020-12-01 Timeless Veterinary Systems International Limited Drug formulary application
SG11201510515YA (en) * 2013-06-20 2016-01-28 Baxalta Inc Providing a pharmacokinetic drug dosing regime
US20150039325A1 (en) * 2013-08-02 2015-02-05 Real Endpoints LLC Assessing Pharmaceuticals
US20150039331A1 (en) * 2013-08-02 2015-02-05 Real Endpoints LLC Assessing pharmaceuticals
WO2015031689A1 (en) 2013-08-30 2015-03-05 Personalis, Inc. Methods and systems for genomic analysis
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
EP3055692A4 (en) * 2013-10-07 2017-07-05 The University Of Chicago Genomic prescribing system and methods
US20150127372A1 (en) * 2013-11-07 2015-05-07 Quintiles Transnational Corporation Electrical Computing Devices Providing Personalized Patient Drug Dosing Regimens
US10943672B2 (en) 2013-12-12 2021-03-09 Ab-Biotics S.A. Web-based computer-aided method and system for providing personalized recommendations about drug use, and a computer-readable medium
US20150269355A1 (en) * 2014-03-19 2015-09-24 Peach Intellihealth, Inc. Managing allocation of health-related expertise and resources
US20170177834A1 (en) * 2014-03-21 2017-06-22 The Regents Of The University Of California Nanomedicine optimization with feedback system control
WO2015143379A1 (en) * 2014-03-21 2015-09-24 Companion Dx Reference Lab, Llc Genomic testing for effective therapies and determination of dosing strategy
CA2953385C (en) 2014-06-30 2024-07-02 Evolving Machine Intelligence Pty Ltd SYSTEM AND METHOD FOR MODELING SYSTEM BEHAVIOR
CN107111673B (zh) * 2014-09-29 2021-03-23 周格尼克斯国际有限公司 控制药物分配的控制系统
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10534895B2 (en) * 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
US20180011977A1 (en) * 2015-03-13 2018-01-11 Ubic, Inc. Data analysis system, data analysis method, and data analysis program
CA2988724C (en) * 2015-04-09 2023-10-10 Diane R. Mould Systems and methods for patient-specific dosing
KR101990951B1 (ko) * 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
US20180358129A1 (en) * 2015-11-26 2018-12-13 Koninklijke Philips N.V. System and method for educating a user about a condition of interest
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
ES3024232T3 (en) 2015-12-22 2025-06-04 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
US12071669B2 (en) 2016-02-12 2024-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for detection of abnormal karyotypes
WO2017149530A1 (en) 2016-02-29 2017-09-08 Mor Research Applications Ltd System and method for selecting optimal medications for a specific patient
EP3223181B1 (en) 2016-03-24 2019-12-18 Sofradim Production System and method of generating a model and simulating an effect on a surgical repair site
US10436771B2 (en) * 2016-04-05 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for targeted therapy based on single-cell stimulus perturbation response
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
CN109478421B (zh) 2016-05-25 2024-07-09 豪夫迈·罗氏有限公司 剂量方案设计相关的材料与方法
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10783997B2 (en) * 2016-08-26 2020-09-22 International Business Machines Corporation Personalized tolerance prediction of adverse drug events
WO2018049250A1 (en) 2016-09-08 2018-03-15 Curematch, Inc. Optimizing therapeutic options in personalized medicine
US20180121617A1 (en) * 2016-10-28 2018-05-03 Pinscriptive, Inc. Treatment Decision Interface Device and Graphical User Interface (GUI)
US20180121616A1 (en) * 2016-10-28 2018-05-03 Pinscriptive, Inc. Systems and Methods for Treatment Decisions
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CA3053245A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
JP2018156149A (ja) * 2017-03-15 2018-10-04 オムロン株式会社 投薬支援装置、方法およびプログラム
US10249389B2 (en) * 2017-05-12 2019-04-02 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
CN107273710A (zh) * 2017-08-22 2017-10-20 北京岙特杰诺生物科技有限公司 一种建立药物代谢酶基因与药物代谢的关系模型的方法
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11153156B2 (en) 2017-11-03 2021-10-19 Vignet Incorporated Achieving personalized outcomes with digital therapeutic applications
WO2019104101A1 (en) * 2017-11-21 2019-05-31 Verisim Life Inc. Systems and methods for full body circulation and drug concentration prediction
EP3729459B1 (en) * 2017-12-21 2026-04-01 Glytec, LLC Advising diabetes medications
US11227692B2 (en) 2017-12-28 2022-01-18 International Business Machines Corporation Neuron model simulation
WO2019195733A1 (en) * 2018-04-05 2019-10-10 University Of Maryland, Baltimore Method and apparatus for individualized administration of medicaments for delivery within a therapeutic range
SG11202009719XA (en) * 2018-04-23 2020-10-29 Diane Mould Systems and methods for modifying adaptive dosing regimens
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
CN112512524A (zh) * 2018-06-06 2021-03-16 米尼奥尔克斯治疗有限公司 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法
RU2695820C1 (ru) * 2018-09-28 2019-07-29 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический центр наркологии Департамента здравоохранения города Москвы" (ГБУЗ "МНПЦ наркологии ДЗМ") Способ прогнозирования оценки эффективности терапии трифлуоперазином для лечения расстройств, сопровождающихся развитием психотической симптоматики
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11965206B2 (en) 2018-12-21 2024-04-23 John Stoddard Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes
US11721441B2 (en) * 2019-01-15 2023-08-08 Merative Us L.P. Determining drug effectiveness ranking for a patient using machine learning
US12347538B2 (en) 2019-02-06 2025-07-01 OptimDosing, LLC Smart multidosing
US11809382B2 (en) 2019-04-01 2023-11-07 Nutanix, Inc. System and method for supporting versioned objects
AU2020279079A1 (en) * 2019-05-21 2022-01-20 Syqe Medical Ltd. Substance delivery planning system
US11676727B2 (en) 2019-08-14 2023-06-13 Optum Technology, Inc. Cohort-based predictive data analysis
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド 単一試料からの腫瘍純度の推定
IT201900024150A1 (it) 2019-12-16 2021-06-16 Persongene Srl Sistema e metodo per la determinazione di un parametro di adeguatezza di un farmaco in funzione di fattori genetici
US11443854B2 (en) * 2020-02-24 2022-09-13 International Business Machines Corporation Identifying potential medicinal interactions for online clinical trial study groups
CN111696678B (zh) * 2020-06-15 2023-05-26 中南大学 一种基于深度学习的用药决策方法和系统
US11127506B1 (en) 2020-08-05 2021-09-21 Vignet Incorporated Digital health tools to predict and prevent disease transmission
US11056242B1 (en) 2020-08-05 2021-07-06 Vignet Incorporated Predictive analysis and interventions to limit disease exposure
US12230406B2 (en) 2020-07-13 2025-02-18 Vignet Incorporated Increasing diversity and engagement in clinical trails through digital tools for health data collection
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11456080B1 (en) 2020-08-05 2022-09-27 Vignet Incorporated Adjusting disease data collection to provide high-quality health data to meet needs of different communities
US11504011B1 (en) 2020-08-05 2022-11-22 Vignet Incorporated Early detection and prevention of infectious disease transmission using location data and geofencing
CN112221023B (zh) * 2020-09-27 2023-12-15 中国辐射防护研究院 一种放射性药物的剂量评估系统及方法
US12001872B2 (en) 2020-10-14 2024-06-04 Nutanix, Inc. Object tiering from local store to cloud store
US11900164B2 (en) 2020-11-24 2024-02-13 Nutanix, Inc. Intelligent query planning for metric gateway
US11822370B2 (en) 2020-11-26 2023-11-21 Nutanix, Inc. Concurrent multiprotocol access to an object storage system
TWI775253B (zh) * 2020-12-24 2022-08-21 宏碁股份有限公司 高風險用藥路徑的計算方法
US12307279B2 (en) 2021-02-01 2025-05-20 Nutanix, Inc. System and method of VM recovery on S3 compatible object storage
US11586524B1 (en) 2021-04-16 2023-02-21 Vignet Incorporated Assisting researchers to identify opportunities for new sub-studies in digital health research and decentralized clinical trials
US11281553B1 (en) 2021-04-16 2022-03-22 Vignet Incorporated Digital systems for enrolling participants in health research and decentralized clinical trials
US11789837B1 (en) 2021-02-03 2023-10-17 Vignet Incorporated Adaptive data collection in clinical trials to increase the likelihood of on-time completion of a trial
US12211594B1 (en) 2021-02-25 2025-01-28 Vignet Incorporated Machine learning to predict patient engagement and retention in clinical trials and increase compliance with study aims
US12248384B1 (en) 2021-02-25 2025-03-11 Vignet Incorporated Accelerated clinical trials using patient-centered, adaptive digital health tools
US12248383B1 (en) 2021-02-25 2025-03-11 Vignet Incorporated Digital systems for managing health data collection in decentralized clinical trials
CN113345600B (zh) * 2021-05-06 2024-02-27 中国食品药品检定研究院 一种抗感染药物注射剂的有效性评价方法及其应用
WO2023059654A1 (en) 2021-10-05 2023-04-13 Personalis, Inc. Customized assays for personalized cancer monitoring
CN113917025B (zh) * 2021-10-09 2024-07-19 上海市精神卫生中心（上海市心理咨询培训中心） 一种定量检测生物样本中精神类药物的试剂盒及其应用
US12032857B2 (en) 2021-11-22 2024-07-09 Nutanix, Inc. System and method for shallow copy
US11705230B1 (en) 2021-11-30 2023-07-18 Vignet Incorporated Assessing health risks using genetic, epigenetic, and phenotypic data sources
US11901083B1 (en) 2021-11-30 2024-02-13 Vignet Incorporated Using genetic and phenotypic data sets for drug discovery clinical trials
WO2023172522A1 (en) * 2022-03-07 2023-09-14 The Regents Of The University Of California Wearable aptamer microneedle patch for continuous minimally-invasive biomonitoring
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
WO2025186702A1 (en) * 2024-03-04 2025-09-12 Cox International Llc Developing evidence-based treatment formulations
CN118098613B (zh) * 2024-03-04 2025-11-11 北京橘兮科技有限公司 基于人工智能的研究和统计分析方案推荐方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126064T2 (de) 1990-06-22 1997-08-28 Hoffmann La Roche Nachweis von schwachen Metabolisierungsreagentien von Drogen
US5844108A (en) 1990-06-22 1998-12-01 Roche Molecular Systems, Inc. Primers targeted to NAT2 gene for detection of poor metabolizers of drugs
FI92241C (fi) 1993-01-28 1994-10-10 Sampower Oy Menetelmä vapaamäntämoottorin tärinän vaimentamiseksi ja tärinävaimennettu vapaamäntämoottori
US5833599A (en) * 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
US6022683A (en) 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
WO1998047087A1 (en) 1997-04-17 1998-10-22 Glaxo Group Ltd. Statistical deconvoluting of mixtures
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
US6653073B1 (en) 1998-02-20 2003-11-25 City Of Hope Association of the serotonin transport (HTT) gene with cardiovascular disease and longevity
AU750822B2 (en) * 1998-04-03 2002-08-01 Triangle Pharmaceuticals, Inc. Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens
US6291175B1 (en) 1998-06-16 2001-09-18 Variagenics, Inc. Methods for treating a neurological disease by determining BCHE genotype
CA2354544A1 (en) 1998-10-01 2000-04-13 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
US6183963B1 (en) 1998-10-23 2001-02-06 Signalgene Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide (ASO) assay
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
US6861217B1 (en) 1998-11-25 2005-03-01 Genaissance Pharmaceuticals, Inc. Variation in drug response related to polymorphisms in the β2-adrenergic receptor
EP1218536A2 (en) 1999-02-12 2002-07-03 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
CA2362533A1 (en) 1999-02-22 2000-08-31 Variagenics, Inc. Gene sequence variations with utility in determining the treatment of disease
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
JP3777858B2 (ja) 1999-03-09 2006-05-24 株式会社エスアールエル 副甲状腺ホルモン受容体遺伝子の多型性によるｐｔｈ反応性予測方法
US6528260B1 (en) 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
US20010034023A1 (en) 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
JP4532750B2 (ja) 1999-04-28 2010-08-25 大日本住友製薬株式会社 Ｃｙｐ２ａ６遺伝子診断法
EP1054066B1 (en) 1999-05-18 2007-10-17 Nipro Corporation Method for anticipating sensitivity to medicine for osteoporosis and a reagent therefor
US6912492B1 (en) 1999-05-25 2005-06-28 University Of Medicine & Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6297014B1 (en) 1999-07-02 2001-10-02 Cedars-Sinai Medical Center Genetic test to determine non-responsiveness to statin drug treatment
US6338039B1 (en) 1999-07-20 2002-01-08 Michael Lonski Method for automated collection of psychotherapy patient information and generating reports and treatment plans
US20020077756A1 (en) 1999-11-29 2002-06-20 Scott Arouh Neural-network-based identification, and application, of genomic information practically relevant to diverse biological and sociological problems, including drug dosage estimation
GB0000896D0 (en) 2000-01-14 2000-03-08 Univ Glasgow Improved analytical chip
EP1248832A4 (en) 2000-01-21 2004-07-07 Variagenics Inc IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
US6675166B2 (en) 2000-02-09 2004-01-06 The John Hopkins University Integrated multidimensional database
ATE526423T1 (de) 2000-04-18 2011-10-15 Virco Bvba Verfahren zum messen des medikamentenwiderstands gegen hcv
US6251608B1 (en) 2000-04-20 2001-06-26 Technion Research & Development Foundation, Ltd. Method of determining a potential of a hyperglycemic patients of developing vascular complications
US20020052761A1 (en) 2000-05-11 2002-05-02 Fey Christopher T. Method and system for genetic screening data collection, analysis, report generation and access
US20020010552A1 (en) 2000-05-26 2002-01-24 Hugh Rienhoff System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network
US20020076774A1 (en) * 2000-06-21 2002-06-20 Chunhua Yan Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
JP2002024385A (ja) 2000-06-30 2002-01-25 Coreflow Technologies:Kk 遺伝子情報管理システム及びその管理方法
CA2414403A1 (en) 2000-07-06 2002-01-17 The Regents Of The University Of California Methods for diagnosis and treatment of psychiatric disorders
US6461902B1 (en) * 2000-07-18 2002-10-08 Institute Of Microelectronics RF LDMOS on partial SOI substrate
EP1356412A2 (en) 2000-08-10 2003-10-29 Glaxo Group Limited A global electronic medicine response profile testing network
US20020091680A1 (en) 2000-08-28 2002-07-11 Chirstos Hatzis Knowledge pattern integration system
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
AU2001275020A1 (en) * 2000-09-21 2002-04-02 Theradoc.Com, Inc. Systems and methods for manipulating medical data via a decision support system
US20020098498A1 (en) 2000-09-29 2002-07-25 Bader Joel S. Method of identifying genetic regions associated with disease and predicting responsiveness to therapeutic agents
US20050060102A1 (en) 2000-10-12 2005-03-17 O'reilly David J. Interactive correlation of compound information and genomic information
US6450956B1 (en) * 2000-11-06 2002-09-17 Siemens Corporate Research, Inc. System and method for treatment and outcome measurement analysis
JP2002197189A (ja) 2000-12-26 2002-07-12 Sanyo Electric Co Ltd 薬品テーラーメイドシステム
US20020082869A1 (en) 2000-12-27 2002-06-27 Gateway, Inc. Method and system for providing and updating customized health care information based on an individual's genome
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
JP2002245171A (ja) 2001-02-13 2002-08-30 Canon Sales Co Inc 医療情報管理装置、その方法、プログラム、記憶媒体
US6828103B2 (en) 2001-02-22 2004-12-07 Wake Forest University Genetic polymorphisms of estrogen receptor alpha associated with favorable response to hormone replacement therapy
US20030170176A1 (en) 2001-03-14 2003-09-11 Mcgill University Individualization of therapy with antipsychotics
US20020187483A1 (en) 2001-04-20 2002-12-12 Cerner Corporation Computer system for providing information about the risk of an atypical clinical event based upon genetic information
WO2003008637A2 (en) * 2001-07-17 2003-01-30 Xanthus Life Sciences, Inc. Use of genotyping in the individualization of therapy
JP2003068878A (ja) 2001-08-23 2003-03-07 Hitachi Ltd 半導体集積回路装置およびその製造方法
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
US7461006B2 (en) 2001-08-29 2008-12-02 Victor Gogolak Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data
US20030105596A1 (en) * 2001-10-29 2003-06-05 Goldstein David Benjamin Methods for evaluating responses of a group of test subjects to a drug or other clinical treatment and for predicting responses in other subjects
US20030104453A1 (en) 2001-11-06 2003-06-05 David Pickar System for pharmacogenetics of adverse drug events
US20030157110A1 (en) 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
US20030204415A1 (en) 2002-04-30 2003-10-30 Calvin Knowlton Medical data and medication selection and distribution system
US7624029B1 (en) * 2002-06-12 2009-11-24 Anvita, Inc. Computerized system and method for rapid data entry of past medical diagnoses
US20040091909A1 (en) * 2002-07-05 2004-05-13 Huang Doug Hui High throughput cytochrome P450 genotyping
JP5348840B2 (ja) * 2003-02-20 2013-11-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 薬物を選択する方法
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
US20040193446A1 (en) * 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
US20050084880A1 (en) 2003-07-11 2005-04-21 Ronald Duman Systems and methods for diagnosing & treating psychological and behavioral conditions
US20050037366A1 (en) 2003-08-14 2005-02-17 Joseph Gut Individual drug safety
US20050069936A1 (en) * 2003-09-26 2005-03-31 Cornelius Diamond Diagnostic markers of depression treatment and methods of use thereof
DE10345837A1 (de) * 2003-10-02 2005-04-21 Bayer Technology Services Gmbh Verfahren zur Bestimmung einer Wirkstoffdosierung
WO2005038049A2 (en) * 2003-10-06 2005-04-28 Heinrich Guenther System and method for optimizing drug therapy
US7813880B2 (en) * 2004-03-25 2010-10-12 University Of Maryland, Baltimore Apparatus and method for providing optimal concentrations for medication infusions
US20080195326A1 (en) * 2004-05-03 2008-08-14 Martin Munzer Method And System For Comprehensive Knowledge-Based Anonymous Testing And Reporting, And Providing Selective Access To Test Results And Report
US20050260549A1 (en) * 2004-05-19 2005-11-24 Feierstein Roslyn E Method of analyzing question responses to select among defined possibilities and means of accomplishing same
US7546285B1 (en) * 2004-09-24 2009-06-09 Sprint Communications Company L.P. System and method for scoring development concepts
ES2347167T3 (es) * 2004-12-21 2010-10-26 Academia Sinica Variantes geneticas de vkorc1 que predicen la sensibilidad a warfarina.
US7914990B2 (en) 2005-01-13 2011-03-29 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
WO2006138202A2 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024192543A1 (es) 2023-03-22 2024-09-26 Neomente Corp Método para la selección de medicamentos para el tratamiento de patologías de salud mental

Also Published As

Publication number Publication date
DK2508621T3 (en) 2015-01-12
JP5567107B2 (ja) 2014-08-06
US20150006190A9 (en) 2015-01-01
US8589175B2 (en) 2013-11-19
EP2508621B1 (en) 2014-11-05
JP2009517186A (ja) 2009-04-30
EP1958111A4 (en) 2009-07-08
CA2911569C (en) 2019-11-26
US20090171697A1 (en) 2009-07-02
EP3703058A1 (en) 2020-09-02
EP1958111A2 (en) 2008-08-20
JP2014176718A (ja) 2014-09-25
AU2006320633A1 (en) 2007-06-07
HK1176093A1 (en) 2013-07-19
WO2007064675A2 (en) 2007-06-07
JP2013059665A (ja) 2013-04-04
US20210166820A1 (en) 2021-06-03
EP3223182A1 (en) 2017-09-27
US20170147779A1 (en) 2017-05-25
JP5894213B2 (ja) 2016-03-23
US20140046684A1 (en) 2014-02-13
CA3060475A1 (en) 2007-06-07
CA2911569A1 (en) 2007-06-07
CA2630604C (en) 2016-01-19
WO2007064675A3 (en) 2008-11-20
CA2630604A1 (en) 2007-06-07
JP2012123837A (ja) 2012-06-28
HK1244906A1 (en) 2018-08-17
EP2508621A1 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
ES2529211T3 (es) Optimización e individualización de la selección y dosificación de medicamentos
Murphy Jr et al. Pharmacogenetics of antidepressant medication intolerance
ES2575903T3 (es) Métodos para seleccionar medicamentos antidepresivos
Rotondo et al. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder
Murphy et al. Serotonin transporter: gene, genetic disorders, and pharmacogenetics
McCracken et al. Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders
Blazquez et al. Fluoxetine pharmacogenetics in child and adult populations
Gelegen et al. Dopaminergic and brain‐derived neurotrophic factor signalling in inbred mice exposed to a restricted feeding schedule
Sampaio et al. Association between polymorphisms in GRIK2 gene and obsessive‐compulsive disorder: A family‐based study
Spellicy et al. A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study
Strausz et al. Genetic analysis of probable sleep bruxism and its associations with clinical and behavioral traits
Tabrizi et al. Genetic markers in sepsis
Greenbaum et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients
Hasanzad et al. Principles of pharmacogenomics and pharmacogenetics
Hervas et al. Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders
Anderson et al. Examination of association to autism of common genetic variationin genes related to dopamine
Berel et al. Interest of fluvoxamine as an add-on to clozapine in children with severe psychiatric disorder according to CYP polymorphisms: experience from a case series
Weerts et al. Independent and Interactive Effects of OPRM 1 and DAT 1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers
Hamidovic et al. Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers
Otmakhov et al. The Role of Pharmacogenetic Testing in Optimizing Antipsychotic Therapy
Webster Pharmacogenetics in pain management: the clinical need
Avilov et al. Predictive pharmacogenetic testing in psychiatry: Pros and cons
Myers et al. New vistas in the management of treatment-refractory psychiatric disorders: Genomics and personalized medicine
Karimi et al. Pharmacogenomic considerations for prescribing the antidepressant fluoxetine: A review in personalized medicine
Schwab et al. Pharmacogenomics in psychiatry